National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting, 38353-38354 [2013-15203]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 123 / Wednesday, June 26, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
testing. Further, the invention rat has a
longer life span so that studies of longer
duration or studies involving serial
sampling can be conducted. The
invention rat can be used to evaluate
potential treatments for AD and to
further investigate AD physiology.
Potential Commercial Applications:
• In vivo validation of AD
therapeutics.
• Development and validation of
imaging methods to diagnose AD.
• Detailed investigation of AD
pathology and physiology.
Competitive Advantages:
• Rat model in contrast to available
mice models.
• Rat model based on over-expression
of genes responsible for early onset AD.
Development Stage:
• Prototype.
• In vivo data available (animal).
Inventors: Robert M. Cohen, et al.
(NIMH).
Publication: Borchelt DR, et al.
Familial Alzheimer’s disease-linked
presenilin 1 variants elevate Abeta1–42/
1–40 ratio in vitro and in vivo. Neuron.
1996 Nov; 17(5):1005–13. [PMID
8938131]
Intellectual Property: HHS Reference
No. E–211–2012/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Lauren NguyenAntczak, Ph.D., J.D.; 301–435–4074;
nguyenantczakla@mail.nih.gov.
Prognostic Biomarkers for Patients
With Early Stage Lung Cancer
Description of Technology:
Investigators at the National Cancer
Institute have discovered a set of
biomarkers that can identify patients
with early stage lung cancer who have
a high risk of relapse. Available for
licensing are prognostic assays based on
these biomarkers, which can enable
clinicians to select more effective
therapy and post-operative follow-up
strategies.
Surgery is the standard care for
patients with stage I lung cancer.
Despite successful surgery, 20–30% of
patients will relapse. Chemotherapy can
improve patient survival; however, it is
controversial if early stage cancer
patients should be treated with
chemotherapy since, for many cases, it
will harm quality of life with little
therapeutic benefit. Utilizing patient
samples, the investigators conducted a
retrospective study in eight patient
cohorts that validated the gene classifier
set. These prognostic methods can guide
physicians to select appropriate
treatment and follow-up while sparing
other patients of unnecessary treatment
and negative side-effects of
chemotherapy.
VerDate Mar<15>2010
20:26 Jun 25, 2013
Jkt 229001
38353
Potential Commercial Applications:
• Method to determine the prognosis
of patients with lung cancer.
• Method to select more effective
treatment and post-operative follow-up
for patients with early stage lung cancer.
Competitive Advantages: Assays were
validated in human tissue samples and
eight different patient cohorts.
Development Stage:
• Early-stage.
• In vivo data available (human).
Inventors: Curt Harris (NCI), Aaron
Schetter (NCI), Ichiro Akagi (Nippon
Medical School), and Hirokazu
Okayama (Fukushima Medical
University).
Publication: Akagi I, et al.
Combination of protein coding and noncoding gene expression as a robust
prognostic classifier in stage I lung
adenocarcinoma. Cancer Res. 2013 May
2; Epub ahead of print. [PMID
23639940]
Intellectual Property: HHS Reference
No. E–048–2012/0—U.S. Provisional
Application No. 61/691,118 filed 20
Aug 2012.
Related Technology: HHS Reference
No. E–181–2006/0—U.S. Patent Nos.
7,943,318 and 8,377,637 and Australian
Patent No. 2007205234, and related
patent applications pending in
Australia, Canada, China, Europe, Japan
and the U.S.
Licensing Contact: Jennifer Wong,
M.S.; 301–435–4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize an early detection test for
lung cancer. For collaboration
opportunities, please contact John
Hewes, Ph.D. at hewesj@mail.nih.gov.
• Stem cell-based regenerative
medicine.
• Cancer therapeutic that targets
cancer stem cells.
Competitive Advantages: The
retroviral and lentiviral vectors in this
invention allow more selective control
of p53 activities than siRNA or mutant
p53 methods.
Development Stage: Early-stage.
Inventors: Curtis C. Harris (NCI) et al.
Intellectual Property: HHS Reference
No. E–239–2010/0—
• U.S. Provisional Patent Application
No. 61/389,134 filed 01 Oct 2010.
• International Patent Application
PCT/US2011/054304 filed 30 Sep 2011,
which published as WO/2012/044979
on 05 Apr 2012.
• Australian Patent Application
2011308567 filed 30 Sep 2011.
• US Patent Application No. 13/
877,100 filed 29 Mar 2013.
• Applications also pending in CA,
EP, JP (filing nos. unknown).
Related Technologies:
• HHS Reference No. E–033–2008/
0—Therapeutic Applications of a p53
Isoform in Regenerative Medicine,
Aging, and Cancer.
• HHS Reference No. E–137–2010/
0—Research Tool. Patent protection is
not being pursued for this technology.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Laboratory of Human Carcinogenesis, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
Retroviral and Lentiviral Vectors. For
collaboration opportunities, please
contact John D. Hewes, Ph.D. at
hewesj@mail.nih.gov.
Retroviral and Lentiviral Vectors To
Increase Efficiency of Inducible
Pluripotent Stem Cell (iPSC) Production
Description of Technology:
Researchers at the National Cancer
Institute have discovered that
modulating a specific p53 isoform
increases the number of inducible
pluripotent stem cells that can be
obtained from cells that are being reprogrammed to obtain pluripotent cells.
It is known that the activity of p53
regulates the self-renewal and
pluripotency of normal and cancer stem
cells, and also affects re-programming
efficiency of iPS cells. This p53 isoformbased technology provides a more
natural process of increasing iPS cell
production than previous methods of
decreasing p53.
Potential Commercial Applications:
Dated: June 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
[FR Doc. 2013–15204 Filed 6–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
E:\FR\FM\26JNN1.SGM
26JNN1
38354
Federal Register / Vol. 78, No. 123 / Wednesday, June 26, 2013 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; Review of Applications on
HIV–AIDS/Alcohol Comparative
Effectiveness & Implementation Research
(RFA AA 13–003, 004).
Date: July 30–31, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIAAA, 5635 Fishers Lane,
Rockville, MD 20852 (Virtual Meeting).
Contact Person: Ranga Srinivas, Ph.D.,
Chief, Extramural Project Review Branch
EPRB, NIAAA, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852 (301) 451–2067,
srinivar @mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.273, Alcohol Research
Programs; National Institutes of Health, HHS)
Dated: June 19, 2013.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–15203 Filed 6–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Dermatology.
VerDate Mar<15>2010
20:26 Jun 25, 2013
Jkt 229001
Date: July 22, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Daniel F McDonald, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4110,
MSC 7814, Bethesda, MD 20892, (301) 435–
1215, mcdonald@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Psychological Health, Development
and Aging.
Date: July 22, 2013.
Time: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Dana Jeffrey Plude, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3176,
MSC 7848, Bethesda, MD 20892, 301–435–
2309, pluded@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Pilot
Clinical Studies in Nephrology and Urology.
Date: July 23–24, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Atul Sahai, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
MSC 7818, Bethesda, MD 20892, 301–435–
1198, sahaia@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Translational Research in Diabetes and
Obesity.
Date: July 24, 2013.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Robert Garofalo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 6156,
MSC 7892, Bethesda, MD 20892, 301–435–
1043, garofalors@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Mental Disorders and Addiction.
Date: July 24, 2013.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Jay Joshi, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Drive, Room 5196, MSC 7846, Bethesda, MD
20892, (301) 408–9135, joshij@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Biodemography of Aging.
Date: July 24, 2013.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 20, 2013.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–15198 Filed 6–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Orthopedic and Skeletal Biology.
Date: July 8–9, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Baljit S Moonga, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7806, Bethesda, MD 20892, 301–435–
1777, moongabs@mail.nih.gov.
E:\FR\FM\26JNN1.SGM
26JNN1
]]>Agencies
[Federal Register Volume 78, Number 123 (Wednesday, June 26, 2013)]
[Notices]
[Pages 38353-38354]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-15203]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
[[Page 38354]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Special Emphasis Panel; Review of Applications on HIV-
AIDS/Alcohol Comparative Effectiveness & Implementation Research
(RFA AA 13-003, 004).
Date: July 30-31, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: NIAAA, 5635 Fishers Lane, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Ranga Srinivas, Ph.D., Chief, Extramural Project
Review Branch EPRB, NIAAA, National Institutes of Health, 5365
Fishers Lane, Room 2085, Rockville, MD 20852 (301) 451-2067,
srinivar @mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program No. 93.273,
Alcohol Research Programs; National Institutes of Health, HHS)
Dated: June 19, 2013.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-15203 Filed 6-25-13; 8:45 am]
BILLING CODE 4140-01-P
